| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019838160 |
| P356 | DOI | 10.1038/KI.2010.132 |
| P932 | PMC publication ID | 2906702 |
| P698 | PubMed publication ID | 20445496 |
| P5875 | ResearchGate publication ID | 44576073 |
| P50 | author | Matthew C Pickering | Q55692581 |
| P2093 | author name string | Philippe Azam | |
| H Terence Cook | |||
| Elena Goicoechea de Jorge | |||
| Fadi Fakhouri | |||
| Frédérique Brune | |||
| P2860 | cites work | Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II) | Q24317382 |
| Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice | Q24651118 | ||
| Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H | Q28114862 | ||
| Familial hemolytic uremic syndrome associated with complement factor H deficiency | Q33336276 | ||
| Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. | Q33338223 | ||
| Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome | Q33364092 | ||
| Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. | Q33364782 | ||
| Secondary failure of plasma therapy in factor H deficiency | Q33372254 | ||
| Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate | Q33374215 | ||
| Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. | Q33378236 | ||
| Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits | Q33379098 | ||
| Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom | Q33386585 | ||
| Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. | Q33504206 | ||
| Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice | Q34537391 | ||
| Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency | Q35552728 | ||
| Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease) | Q35833465 | ||
| Membranoproliferative glomerulonephritis type II (dense deposit disease): an update | Q36084453 | ||
| Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis | Q36231096 | ||
| New approaches to the treatment of dense deposit disease | Q36860946 | ||
| Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice | Q37362130 | ||
| Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase | Q41443111 | ||
| Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis | Q41885401 | ||
| Serum C'3 lytic system in patients with glomerulonephritis | Q44885697 | ||
| Hypocomplementemic glomerulonephritis in an infant and mother. Evidence for an abnormal form of C3. | Q45079393 | ||
| Porcine membranoproliferative glomerulonephritis type II: an autosomal recessive deficiency of factor H. | Q51047671 | ||
| Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H | Q57089510 | ||
| C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase | Q67740087 | ||
| Eradication of porcine factor H deficiency in Norway | Q73319459 | ||
| In situ complement activation in porcine membranoproliferative glomerulonephritis type II | Q74165088 | ||
| Mouse podocyte complement factor H: the functional analog to human complement receptor 1 | Q79896677 | ||
| C3 deposition glomerulopathy due to a functional factor H defect | Q81654240 | ||
| An inherited defect in the C3 convertase, C3b,Bb, associated with glomerulonephritis | Q93856155 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 279-286 | |
| P577 | publication date | 2010-05-05 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice | |
| P478 | volume | 78 |
| Q35922386 | Alternative Pathway Inhibition by Exogenous Factor H Fails to Attenuate Inflammation and Vascular Leakage in Experimental Pneumococcal Sepsis in Mice |
| Q51730313 | An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. |
| Q42625961 | An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. |
| Q21202864 | Atypical hemolytic uremic syndrome |
| Q37644173 | C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo. |
| Q35531724 | CFH 184G as a genetic risk marker for anterior uveitis in Chinese females |
| Q40821027 | Complement Factor H Serum Levels Determine Resistance to Pneumococcal Invasive Disease |
| Q36145970 | Complement factor H and interleukin gene polymorphisms in patients with non-infectious intermediate and posterior uveitis |
| Q92294442 | Complement factor H contributes to mortality in humans and mice with bacterial meningitis |
| Q39036058 | Complement factor H in host defense and immune evasion. |
| Q33411137 | Complement regulation in renal disease models |
| Q26795441 | Complement regulation: physiology and disease relevance |
| Q38614302 | Complement, a target for therapy in inflammatory and degenerative diseases. |
| Q33396792 | Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome |
| Q37286653 | Dense deposit disease and C3 glomerulopathy |
| Q35124165 | Dense deposit disease. |
| Q37017177 | Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. |
| Q40865063 | Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy |
| Q90496015 | Emerging immunotherapies for autoimmune kidney disease |
| Q58831414 | Endothelial progenitor cell-derived extracellular vesicles protect from complement-mediated mesangial injury in experimental anti-Thy1.1 glomerulonephritis |
| Q43083299 | Expression of human complement factor H prevents age-related macular degeneration-like retina damage and kidney abnormalities in aged Cfh knockout mice |
| Q34699741 | Factor H binds to the hypervariable region of many Streptococcus pyogenes M proteins but does not promote phagocytosis resistance or acute virulence |
| Q35030648 | Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees |
| Q36016859 | IgM exacerbates glomerular disease progression in complement-induced glomerulopathy |
| Q35922195 | Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles |
| Q36509318 | Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency |
| Q33437488 | Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders |
| Q38770928 | Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro |
| Q33410111 | Novel use of intravenous immunoglobulin G in complement factor H missense mutation: a case report |
| Q38048606 | Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. |
| Q38991019 | Protection of host cells by complement regulators. |
| Q38088187 | Recent insights into C3 glomerulopathy |
| Q38591917 | Role of complement in glomerular diseases |
| Q36563619 | Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. |
| Q37260204 | Soluble CR1 therapy improves complement regulation in C3 glomerulopathy |
| Q40715358 | The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in Monocyte-Derived Dendritic Cells |
| Q35624672 | Treatment options for C3 glomerulopathy |
| Q33403607 | Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies |
| Q27318468 | Virulence of Group A Streptococci Is Enhanced by Human Complement Inhibitors |
Search more.